Abcely

Abcely is an early-stage biotech developing the world's first platform for orally active secretory IgA (sIgA) immunotherapies, targeting high-value markets in mucosal oncology and inflammatory diseases. Its proprietary technology aims to rapidly generate optimized drug candidates with superior mucosal targeting and penetration compared to conventional IgG antibodies. The company operates a dual business model of building its own pipeline and pursuing out-licensing opportunities, with three disclosed preclinical programs in colorectal cancer, endometriosis, and inflammatory bowel disease.

Proprietary platform for rapid development of orally active secretory IgA (sIgA) antibodies, featuring Bio Better sIgA CDR grafting technology for creating optimized, mucosal-targeted biologic drug candidates.

Abcely claims no direct competition in developing oral sIgA therapeutics. However, it competes indirectly with all companies developing therapies for colorectal cancer, endometriosis, and IBD, including major pharma with injectable/biologic therapies, oral small molecules, and other novel modalities, creating a crowded and well-funded competitive environment.